Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Table 2

Pharmacokinetic parameters and statistical analysis of atazanavir after administration of atazanavir/ritonavir 300/100 mg qd for two weeks in combination with two NRTIs (Day −1), followed by administration of etravirine 200 mg bid for two weeks in combination with one NRTI and atazanavir/ritonavir 300/100 mg qd or atazanavir/ritonavir 400/100 mg qd (Week 2).

Pharmacokinetics of atazanavir mean ± SD; : median (range)	Group one		Group two
	ATV/r 300/100 mg qd + two NRTIs; (reference); (^*)	ATV/r 300/100 mg qd +; one NRTI + ETR 200 mg bid (Test 1); (^†)	ATV/r 300/100 mg qd + two NRTIs; (reference); (^‡)	ATV/r 400/100 mg qd + one NRTI + ETR 200 mg bid (Test 2); ()
, ng/mL	1339 ± 1728	845.7 ± 703.3	1898 ± 2298	1545 ± 1296
, ng/mL	1104 ± 1511	758.6 ± 610.5	1671 ± 2310	1107 ± 866.8
, ng/mL	5652 ± 2735	5232 ± 2166	6419 ± 2853	6950 ± 2693
, h	4.00 (1.98–6.00)	3.00 (1.00–4.17)	3.04 (1.00–6.00)	3.21 (1.25–6.17)
, ng⋅h/mL	60030 ± 39690	55070 ± 21860	74210 ± 55480	72220 ± 34600
LSM ratio (90% CI) of test versus reference
	0.82 (0.55–1.22)		0.91 (0.63–1.33)
	0.96 (0.80–1.16)		1.05 (0.86–1.27)
	0.96 (0.76–1.22)		0.99 (0.81–1.21)

ATV/r: atazanavir/ritonavir; : area under the plasma concentration-time curve from time 0 to 24 hours; bid: twice daily; CI: confidence interval; : maximum plasma concentration; : minimum plasma concentration; : predose plasma concentration; ETR: etravirine; LSM: least square mean; NRTI: nucleoside reverse transcriptase inhibitor; qd: once daily; SD: standard deviation; : time to maximum plasma concentration.
^* for , for ; ^† for , , and ; ^‡ for , , and ; for , for ;  calculated based on log-transformed pharmacokinetic parameters.